Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CervoMed (CRVO) Equity Average (2022 - 2025)

CervoMed's Equity Average history spans 8 years, with the latest figure at $29.7 million for Q3 2025.

  • For Q3 2025, Equity Average fell 61.62% year-over-year to $29.7 million; the TTM value through Sep 2025 reached $29.7 million, down 61.62%, while the annual FY2024 figure was $23.3 million, 279.78% up from the prior year.
  • Equity Average for Q3 2025 was $29.7 million at CervoMed, down from $34.0 million in the prior quarter.
  • Across five years, Equity Average topped out at $85.8 million in Q2 2024 and bottomed at -$34.4 million in Q2 2023.
  • The 4-year median for Equity Average is $29.7 million (2025), against an average of $16.1 million.
  • The largest annual shift saw Equity Average tumbled 16290.92% in 2023 before it skyrocketed 706.56% in 2024.
  • A 4-year view of Equity Average shows it stood at -$32.6 million in 2022, then surged by 126.03% to $8.5 million in 2023, then surged by 400.5% to $42.4 million in 2024, then dropped by 29.93% to $29.7 million in 2025.
  • Per Business Quant, the three most recent readings for CRVO's Equity Average are $29.7 million (Q3 2025), $34.0 million (Q2 2025), and $36.9 million (Q1 2025).